Dr. Salvador G. Alvarez

    Dr. Salvador G. Alvarez joined Genelabs in 2005 to focus on the discovery of small-molecule anti-infective agents. He's concentrating his drug discovery research efforts in the small-molecule non-nucleoside Hepatitis C Virus (HCV) Inhibitors Program.

    From 2004 to 2005, Dr. Alvarez was in the Oncology Program of Cytokinetics in the small-molecule mitotic kinesins inhibitors project in collaboration with GlaxoSmithKline.

    From 2000 to 2004, Dr. Alvarez was with Vicuron (formerly Versicor) in the small-molecule antibiotics reverse hydroxamates (N-formyl hydroxylamines) project of the Peptide Deformylase (PDF) Inhibitors Program in collaboration with Novartis. His research efforts contributed to the discovery of a "First in Class" PDF oral antibiotic, the First Phase I Clinical Candidate (Y2003Q4) developed at Vicuron.

    From 1998 to 2000, Dr. Alvarez was a Postdoctoral Research Fellow in the small-molecule Matrix Metalloproteases (MMP) Inhibitors Program of the Oncology Therapeutic Area of Novartis in Japan.

    From 1997 to 1998, Dr. Alvarez was a Visiting Assistant Professor at Tokyo University of Agriculture and Technology in Tokyo.

    From 1995 to 1997, Dr. Alvarez was a National Science Foundation/Japan Society for the Promotion of Science (NSF/JSPS) Postdoctoral Research Fellow at Waseda University in Tokyo. Dr. Alvarez received his Ph.D. in Organic Chemistry from the University of California at Santa Cruz (1995), and his B.A. in Chemistry from the University of California at Davis (1989).